CRISPR Therapeutics (CRSP) reported Tuesday a Q4 loss of $0.44 per diluted share, swinging from earnings of $1.10 a year earlier.
Analysts polled by FactSet expected a loss of $1.20.
Total revenue for the quarter ended Dec. 31 was $35.7 million, down from 201.2 million a year earlier.
Analysts surveyed by FactSet expected $8.1 million.
As of Dec. 31, the company had about $1.90 billion in cash, cash equivalents, and marketable securities, compared with about $1.7 billion a year earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。